GnRH agonist

Phase 3Small molecule

Johnson & Johnson

GnRH agonist is one of 181 small molecule programs targeting Central precocious puberty. It is currently in Phase 3.

Indications

Total Trials

Active Trials

180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Precocious PubertyActive, not recruiting

SarcopeniaActive, not recruiting

Salivary Gland NeoplasmsActive, not recruiting

Early-Stage Breast CancerNot yet recruiting

Luteal Phase SupportUnknown status

PrepUnknown status

TrialActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

EndometriosisRecruiting

TreatmentRecruiting

Central Precocious PubertyPreclinical

Active, not recruiting

SarcopeniaPreclinical

Active, not recruiting

Salivary Gland NeoplasmsPhase 2

Active, not recruiting

Early-Stage Breast CancerPreclinical

Not yet recruiting

Luteal Phase SupportPreclinical

Unknown status

PrepPreclinical

Unknown status

TrialPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Active, not recruiting

EndometriosisPhase 3

Recruiting

TreatmentPhase 3

Recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

GnRH agonist

Johnson & Johnson

Phase 3

1 2

Biltricide

Bayer

Preclinical

4 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Theo-Dur

Pfizer

Preclinical

1 7

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 8

Foscavir

CClinigen, Inc.

Preclinical

6 9

Intuniv

PPromius Pharma, LLC

Preclinical

1 10

Reminyl

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Cutaneous T-Cell Lymphoma

NCT06485219

Q4 2027

Phase 2Active, not recruiting

Salivary Gland Neoplasms

NCT04325828

Q1 2028

Phase 2Active, not recruiting

Trial

NCT04025372

Q4 2028

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT02531516

Clinical

Trials by Indication[1]

Embryo Transfer3 trials

Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer

Not yet recruiting·NNational Taiwan University Hospital·Phase 4·NCT07269392·170 enrolled

Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist

Completed·—·Phase 3·NCT02736032·310 enrolled

RESCUE PROTOCOL AND FRESH EMBRYO TRANSFER

Completed·IIstituto Clinico Humanitas··NCT03837223·271 enrolled

Endometriosis3 trials

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Recruiting·HHopital Foch·Phase 2/3·NCT04356664·180 enrolled

Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 3·NCT01125488·80 enrolled

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00458458·112 enrolled

Ovarian Stimulation3 trials

Random-start Ovarian Stimulation in Egg-donors (ROSE)

Terminated·IInstituto Bernabeu·Phase 4·NCT02821819·15 enrolled

The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol

Unknown status·EEuropean Hospital·Phase 3·NCT01636505·200 enrolled

Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone

Unknown status·CCRG UZ Brussel·N/A·NCT05521828·50 enrolled

Prostate Cancer2 trials

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01546987·239 enrolled

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00079001·645 enrolled

Cardiovascular Events1 trial

Cardiovascular Events in GnRH Agonist vs. Antagonist

Unknown status·RRabin Medical Center·Phase 2·NCT04182594·80 enrolled

24 more indications

Central precocious puberty1 trial

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed· Takeda logo

Takeda··NCT02993926·108 enrolled

CLE1 trial

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles

Completed·—·Phase 4·NCT04008966·160 enrolled

Pregnancy1 trial

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

Unknown status·SShaare Zedek Medical Center·N/A·NCT05838105·144 enrolled

Diagnosis1 trial

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

Completed·UUniversitair Ziekenhuis Brussel·Phase 4·NCT01888744·120 enrolled

In Vitro Fertilization1 trial

Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment

Unknown status·UUniversity of Sao Paulo·Phase 3·NCT00948805·25 enrolled

Infants1 trial

Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

Completed·OOrganon and Co··NCT00724789·2,066 enrolled

Metabolism1 trial

Females, Aging, Metabolism, and Exercise

Completed·UUniversity of Colorado, Denver·N/A·NCT01712230·47 enrolled

PrEP1 trial

LH Response to GnRH Test in Prepubescent Girls Under 6 Years

Unknown status·UUniversity of Aarhus·N/A·NCT01944488·60 enrolled

Trial1 trial

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting·—·Phase 2·NCT04025372·234 enrolled

Luteal Phase Support1 trial

GnRH Agonist for Luteal Phase Support.

Unknown status·SShaare Zedek Medical Center·N/A·NCT05484193·150 enrolled

Treatment1 trial

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Recruiting·WWest China Second University Hospital·Phase 2/3·NCT03463252·224 enrolled

Oocyte Maturation1 trial

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Terminated·UUConn Health·Phase 4·NCT01606709·7 enrolled

Sarcopenia1 trial

Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Completed·SSeattle Institute for Biomedical and Clinical Research··NCT03867357·60 enrolled

Aspirin1 trial

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Unknown status·—·Phase 4·NCT03263299·120 enrolled

Adenomyosis1 trial

Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis

Withdrawn·UUniversity Hospital, Toulouse·Phase 3·NCT03940807

Cutaneous T-cell lymphoma1 trial

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Active, not recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 2·NCT06485219·50 enrolled

Frozen Embryo Transfer1 trial

Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles

Unknown status·RRoyan Institute·Phase 3·NCT02251925·460 enrolled

Testosterone1 trial

Efficacy of an Intranasal Testosterone Product

Completed·AAcerus Pharmaceuticals Corporation·Phase 2·NCT01252745·22 enrolled

Intracytoplasmic Sperm Injection1 trial

Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients

Completed·KKasr El Aini Hospital·N/A·NCT02737800·88 enrolled

Endometrial1 trial

Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success

Completed·—··NCT02381821·82 enrolled

Salivary Gland Neoplasms1 trial

An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04325828·31 enrolled

Prostatic Neoplasms1 trial

ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT02531516·1,503 enrolled

Early-stage Breast Cancer1 trial

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Not yet recruiting·UUniversity of Illinois at Chicago·Preclinical·NCT07596212·100 enrolled

Unspecified1 trial

Antagonist/Letrozole in Poor Responders

Completed·YYazd Research & Clinical Center for Infertility·Phase 1/2·NCT00823004·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 36 trial records for GnRH agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

GnRH agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Embryo Transfer3 trials

Endometriosis3 trials

Ovarian Stimulation3 trials

Prostate Cancer2 trials

Cardiovascular Events1 trial

Central precocious puberty1 trial

CLE1 trial

Pregnancy1 trial

Diagnosis1 trial

In Vitro Fertilization1 trial

Infants1 trial

Metabolism1 trial

PrEP1 trial

Trial1 trial

Luteal Phase Support1 trial

Treatment1 trial

Oocyte Maturation1 trial

Sarcopenia1 trial

Aspirin1 trial

Adenomyosis1 trial

Cutaneous T-cell lymphoma1 trial

Frozen Embryo Transfer1 trial

Testosterone1 trial

Intracytoplasmic Sperm Injection1 trial

Endometrial1 trial

Salivary Gland Neoplasms1 trial

Prostatic Neoplasms1 trial

Early-stage Breast Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News